- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04561765
Innovation in the Treatment of Persistent Pain in Adults With NF1: Implementation of the iCanCope Mobile Application- Clinical Trial
September 13, 2022 updated by: Yale University
To demonstrate the initial feasibility and determine preliminary impact on clinical outcomes of the iCanCope-NF program in a pilot RCT.
If successful this pilot study will support conducting a larger randomized control trial (RCT).
The primary research question is what is the feasibility of the iCanCope-NF program?
The investigators define feasibility as (1) rates of accrual and dropout, daily log-ins, engagement, and outcome measures completed and (2) perceptions regarding intervention acceptability and satisfaction; and what are the levels of engagement.
log-ins, with the intervention?
The secondary questions are: (1) how does the iCanCope-NF program compare with the control condition in differences of pain and pain-related activity limitations, sleep functioning, emotional functioning (depression, anxiety), opioid usage, pain catastrophizing, self-efficacy, respondent burden (i.e.
Physical Functioning, R, Vitality, Social Functioning, Role-Emotional, and Mental Health), and psychological flexibility immediately post-treatment (T2), (2) does the iCanCope-NF + CM increase the engagement of the iCanCope-NF program as compared to iCanCope-NF without CM, and do their corresponding levels of pain and pain-related activity decrease with CM?, and (3) do individuals with NF1 utilize the MBAA to help reduce pain symptoms?
The investigators hypothesize that by customizing and including MBAA to the program for adults with NF1, that individuals who engage regularly as seen through Analytics Platform for Evaluating Effective Engagement (APEEE) application, will acquire new sets of skills to facilitate pain management, while pain as reported with the Brief Pain Inventory will decrease.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
108
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Frank D Buono, PHD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 72 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- adults 18+
- able to read and understand English at 5th grade level
- permanently reside in the United States
- have pain interference aggregate scores of three or more in the last two weeks using the Brief Pain Inventory-Short Form (BPI-SF) scale
Exclusion Criteria:
- have an undiagnosed case of NF1
- have documented major co-occurring psychiatric disease
- have moderate to severe cognitive deficits
- have depression assessed using the Patient Health Questionnaire (PHQ-9) or anxiety assessed using the Generalized Anxiety Disorder scale (GAD-7) greater than or equal to the appropriate thresholds (10=mild major depression; 5=mild severe anxiety)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: FACTORIAL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: iCanCope
In this group, individuals will receive the iCanCope-NF program.
The intervention will be delivered on a restricted password-protected mobile application.
Participants will be encouraged to log onto the pain diary app (via automated alerts) once per day over the 8-week period to complete pain diary entries and develop and track their goals related to their pain, physical, social activities, sleep, as well as work through content based on their goals.
|
The iCanCope mobile and web-based self-management program has been empirically evaluated for multiple painful diseases
|
EXPERIMENTAL: iCanCop+Contingency Management
In addition to the iCanCope-NF activities outlined above, individuals will be rewarded with incentives (contingency management) such as points that are redeemable for prize-based gift card vouchers.
Points will be accrued through access to new sections, daily check-ins, and engagement of the mobile application.
Based on research, the total amount of money that can be earned by the patient over the course of the two months is 50 dollars USD.
|
In addition to the iCanCope-NF activities outlined above, individuals will be rewarded with incentives (contingency management) such as points that are redeemable for prize-based gift card vouchers.
Points will be accrued through access to new sections, daily check-ins, and engagement of the mobile application.
Based on research, the total amount of money that can be earned by the patient over the course of the two months is 50 dollars USD.
|
NO_INTERVENTION: Control Group
The control group is designed to assess for potential effects on outcomes of time, attention, during the study.
In addition to usual care, participants will be required to complete baseline and follow-up assessments similar to that of the intervention groups.
They will be given that patient education, through preapproved flyers and information found from national websites regarding pain management, but no self-management strategies or opportunities for social support.
They will not have access to the mobile application during the course of experiment; however, the control group will be offered the full iCanCope-NF program following the trial (T2) for a period of 2 months after the study is over.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Engagement Activity
Time Frame: through the completion of the study, on average 4 months.
|
Total minutes logged on the mobile application will be evaluated between the two groups using the mobile application.
|
through the completion of the study, on average 4 months.
|
Pain Severity
Time Frame: through the completion of the study, on average 4 months.
|
A comparison within groups change of pain severity measured by the Brief Pain Inventory-Short Form.
Respondents rate items on a 0-10 scale to indicate the pain severity and interference, and the total score is the mean of each subfactor.
The higher the score indicates more severity and interference of pain.
|
through the completion of the study, on average 4 months.
|
Pain Interference Index
Time Frame: through the completion of the study, on average 4 months.
|
A comparison within groups change of pain interference measured by the Pain Interference Index Scale.
Respondents rate items on a 0-6 scale to indicate how much pain has interfered with various activities, and the total score is the mean of the six items.
Where 6 indicates high interference.
|
through the completion of the study, on average 4 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment Services Review
Time Frame: through the completion of the study, on average 4 months.
|
what are perceptions of satisfaction across groups exposed to the iCanCope mobile application using an The Treatment Services Review (TSR)
|
through the completion of the study, on average 4 months.
|
Anxiety
Time Frame: through the completion of the study, on average 4 months.
|
A comparison within change of generalized anxiety measured by the generalized anxiety disorder scale (GAD-7).
After reading each statement, one of four choices are provided and respondents can select one response (1=not at all sure, 2=several days, 3=over half days, 4=nearly every day).
Each column is then added, and a total score is obtained, with scores falling into four levels of anxiety, including minimal (1-4), mild (5-9), moderate (10-14), and severe (15-21)
|
through the completion of the study, on average 4 months.
|
Sleep functioning
Time Frame: through the completion of the study, on average 4 months.
|
A comparison within change of sleep quality measured by the PROMIS Sleep inventory.
The higher the total score, the more severe the symptom.
Total scores less than 24 suggest no to slight sleep disturbance, 24-28 suggest mild disturbance, 29-38 moderate disturbance, and greater than 38 severe sleep disturbance
|
through the completion of the study, on average 4 months.
|
Short Form/Quality of Life
Time Frame: through the completion of the study, on average 4 months.
|
the Short form survey 20- will measure quality of life across 8 subscales on respondent burden (Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health).
Scores were transformed linearly to 0-100 scales, with 0 and 100 assigned to the lowest and highest possible scores, where high value indicated better functioning.
|
through the completion of the study, on average 4 months.
|
Chronic pain acceptance
Time Frame: through the completion of the study, on average 4 months.
|
Chronic Pain Acceptance Questionnaire-Revised (CPAQ-Revised) 20-item scale designed to measure acceptance of pain.
The acceptance of chronic pain is thought to reduce unsuccessful attempts to avoid or control pain and thus focus on engaging in valued activities and pursuing meaningful goals will be measured across all groups.
The items on the CPAQ are rated on a 7-point scale from 0 (never true) to 6 (always true).
To score the CPAQ, add the items for Activity engagement and Pain willingness to obtain a score for each factor.
To obtain the total score, add the scores for each factor together.
Higher scores indicate higher levels of acceptance
|
through the completion of the study, on average 4 months.
|
psychological inflexibility
Time Frame: through the completion of the study, on average 4 months.
|
Psychological Inflexibility in Pain Scale (PIPS) 16-item scale used to assess psychological inflexibility (i.e.
avoidance, acceptance, fusion, values orientation, dirty discomfort) in people with chronic pain will be measured across all groups.
Respondents are asked to rate items on a 7-point scale that ranges from 1 (never true) to 7 (always true).
Higher scores indicate greater levels of psychological inflexibility.
|
through the completion of the study, on average 4 months.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mindfulness based alternative approaches (MBAA)
Time Frame: through the completion of the study, on average 4 months.
|
Do individuals with NF1 utilize the MBAA more readily because they are on the mobile application, via Five Facet Mindfulness Questionnaire.
39-item self-completed questionnaire measuring the five facets of mindfulness: Observing (8 items), Describing (8 items), Acting with awareness (8 items), Non-judgmental (8 items), and Non-reactive (7 items).
Participants rated the items on a five-point Likert scale (1 = never or very rarely true to 5 = very often or always true), each facet score ranges from 8 to 40, except for the non-reactive facet which ranges from 7 to 35.
|
through the completion of the study, on average 4 months.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
March 1, 2021
Primary Completion (ACTUAL)
September 6, 2022
Study Completion (ACTUAL)
September 6, 2022
Study Registration Dates
First Submitted
September 10, 2020
First Submitted That Met QC Criteria
September 22, 2020
First Posted (ACTUAL)
September 24, 2020
Study Record Updates
Last Update Posted (ACTUAL)
September 14, 2022
Last Update Submitted That Met QC Criteria
September 13, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Pain
- Neurologic Manifestations
- Genetic Diseases, Inborn
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Neoplasms, Nerve Tissue
- Peripheral Nervous System Diseases
- Nervous System Neoplasms
- Heredodegenerative Disorders, Nervous System
- Neoplastic Syndromes, Hereditary
- Nerve Sheath Neoplasms
- Neurocutaneous Syndromes
- Peripheral Nervous System Neoplasms
- Chronic Pain
- Neurofibromatoses
- Neurofibromatosis 1
- Neurofibroma
Other Study ID Numbers
- 2000029045
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
IPD will not be shared with other investigator.
Only non-PHI/IPD will be shared.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Pain
-
Pain ConcernThe Thistle Foundation; Health and Social Care Alliance Scotland (the ALLIANCE) and other collaboratorsCompletedChronic Pain | Chronic Pain Syndrome | Chronic Pain, Widespread | Chronic Pain Due to Trauma | Chronic Pain Due to Malignancy (Finding) | Chronic Pain Due to Injury | Chronic Pain Post-Procedural | Chronic Pain HipUnited Kingdom
-
Consorci Sanitari de l'Alt Penedès i GarrafRecruitingChronic Post Operative Pain | Chronic Post-surgical Pain | Chronic Knee PainSpain
-
University of Alabama, TuscaloosaPatient-Centered Outcomes Research Institute; East Carolina University; Whatley...CompletedPain | Chronic Pain | Chronic Pain Syndrome | Widespread Chronic Pain | Chronic Pain Due to InjuryUnited States
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
University of UtahRecruitingChronic Pain | Chronic Pain Syndrome | Widespread Chronic PainUnited States
-
Evolve Restorative CenterFlowonix Medical; Celéri Health, Inc.; Advanced Infusion SolutionsCompletedPain, Chronic | Pain, Intractable | Chronic Nonmalignant PainUnited States
-
Assiut UniversityNot yet recruiting
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
-
Istanbul UniversityCompletedLow Back Pain, Mechanical, Biofeedback, Pain, Chronic
-
Apurano Pharmaceuticals GmbHRecruitingPain | Lower Back Pain | Back Pain | Chronic Pain | Pain, Chronic | Chronic Pain Syndrome | Pain Syndrome | Lower Back Pain ChronicGermany
Clinical Trials on iCanCope
-
The Hospital for Sick ChildrenAlberta Children's Hospital; British Columbia Children's HospitalCompletedJuvenile Idiopathic ArthritisCanada
-
University of AgderThe Hospital for Sick ChildrenCompleted
-
The Hospital for Sick ChildrenBoston Children's HospitalRecruitingPain, Chronic | Pain, Chronic Post-SurgicalCanada, United States
-
The Hospital for Sick ChildrenUniversity of Alberta; University of Toronto; The Ottawa Hospital; Hamilton Health... and other collaboratorsCompleted